New Alzheimer’s drug clouds outlook for Medicare premiums next year
The decision by U.S. drug regulators last month to approve a controversial treatment for Alzheimer’s disease could fuel an unusually large increase in Medicare premiums next year, but the outlook is clouded by a number of factors that will play out later this year.
Read the full article.
Tags
bioethics fda health law policy pharmaceuticals rachel sachs regulation